With 0.29 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.2485 whereas the lowest price it dropped to was $1.1701. The 52-week range on BCLI shows that it touched its highest point at $6.94 and its lowest point at $0.72 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 0.21.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCLI was down-trending over the past week, with a drop of -2.42%, but this was down by -11.03% over a month. Three-month performance dropped to -22.44% while six-month performance fell -16.55%. The stock lost -82.84% in the past year, while it has lost -46.70% so far this year. A look at the trailing 12-month EPS for BCLI yields -1.98 with Next year EPS estimates of -0.93. For the next quarter, that number is -0.37. This implies an EPS growth rate of 30.74% for this year and 41.88% for next year. EPS is expected to grow by 29.48% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 32.00%.
Float and Shares Shorts:
At present, 7.91 million BCLI shares are outstanding with a float of 6.17 million shares on hand for trading. On 2025-05-30, short shares totaled 0.54 million, which was 676.0000400000001 higher than short shares on 1745971200. In addition to Mr. Chaim Lebovits as the firm’s President & CEO, Dr. Ibrahim Dagher M.D. serves as its Executive VP & Chief Medical Officer.
Institutional Ownership:
Through their ownership of 0.12891 of BCLI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, BCLI reported revenue of $0.0 and operating income of -$3089000.0. The EBITDA in the recently reported quarter was -$3216000.0 and diluted EPS was -$0.45.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCLI since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCLI analysts setting a high price target of 24.35 and a low target of 6.0, the average target price over the next 12 months is 13.11667. Based on these targets, BCLI could surge 1912.4% to reach the target high and rise by 395.87% to reach the target low. Reaching the average price target will result in a growth of 984.02% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.1 being high and -$2.1 being low. For BCLI, this leads to a yearly average estimate of -$2.1.
